Abstract: The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike(S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.

Abstract: The present disclosure provides recombinant fusogenic proteins comprising a rhabdovirus glycoprotein (G) and a targeting molecule attached to the N-terminus of the rhabdovirus glycoprotein. Further provided are related recombinant polynucleotides, host cells, and pharmaceutical compositions. Recombinant viruses, e.g., recombinant pseudotyped viruses, and cell-derived nanovesicles comprising the recombinant polynucleotides are also provided. Further provided are methods for using the recombinant fusogenic proteins, polynucleotides, viruses, and cell-derived nanovesicles, and/or pharmaceutical compositions thereof, including their use in the treatment of cancer.

Abstract: The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.